Picture of Bavarian Nordic A/S logo

BAVA — Bavarian Nordic A/S News Story

0.000.00%
dk flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Denmark's Vaccine maker Bavarian Nordic Q3 EBITDA margin rises, upgrades FY outlook

Denmark's Vaccine maker Bavarian Nordic Q3 EBITDA margin rises, upgrades FY outlook


Overview

  • Denmark vaccine maker's Q3 revenue was flat yr/yr at DKK 1,805 mln

  • Q3 EBITDA margin rose to 34.4%, up from 29% last year

  • Company completed DKK 500 mln share buyback, launched new program up to DKK 750 mln


Outlook

  • Company maintains full-year 2026 revenue guidance of about DKK 6,100 mln

  • Bavarian Nordic expects 2026 EBITDA margin to reach about 32%

  • Company says outlook reflects increased investment levels in Q4


Result Drivers

  • TRAVEL HEALTH GROWTH - Co said Q3 Travel Health revenue rose 22%, driven by strong RabAvert/Rabipur sales and Vimkunya launch

  • PRODUCT AND MARKET MIX - Co said higher gross margin was due to strong topline and advantageous product and market mix

  • PUBLIC PREPAREDNESS STABLE - Public Preparedness revenue was in line with expectations, supporting overall performance


Company press release: ID:nGNE1hmS3


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

DKK 1.81 bln

Q3 EBITDA

DKK 621 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Bavarian Nordic A/S is DKK280.00, about 16.8% above its November 12 closing price of DKK239.80

  • The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 21 three months ago


Reuters Recommended Reads

  • Nov 10 - Lundbeck hikes annual forecasts as migraine drug powers earnings beat

  • Nov 10 - Denmark's Lundbeck posts higher Q3 profit, raises FY revenue and EBITDA guidance

  • Nov 12 - Zealand Pharma seeks partners for rare-disease assets as obesity focus grows


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Bavarian Nordic A/S

See all news